Arthur Kavanaugh.

Philip J. Mease, M.D ., Iain B. McInnes, Ph.D., Bruce Kirkham, M.D., Arthur Kavanaugh, M.D., Proton Rahman, M.D.D., Ph.D.D., Ph.D., Peter Nash, M.B., B.S., Luminita Pricop, M.D., Jiacheng Yuan, Ph.D., Hanno B. Richards, M.D., and Shephard Mpofu, M.D. For the FUTURE 1 Research Group: Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis Psoriatic arthritis is usually a persistent, systemic inflammatory disease that affects peripheral joints, connective tissues, and the axial skeleton and is associated with psoriasis of the nails and pores and skin.1,2 Inhibitors of tumor necrosis aspect possess significantly improved outcomes among sufferers with psoriatic arthritis.3-6 However, some patients who’ve received these agents have not had adequate advantage, have not had a durable response, or experienced adverse events.1,2 Effective therapies with a different system of action are needed.

Research in this patient population show that the more intense P2Y12-receptor inhibition achieved with the use of prasugrel, ticagrelor, or cangrelor, as compared with clopidogrel, is associated with better scientific outcomes and a lesser risk of stent thrombosis.1-5 The benefit was obtained with in-hospital administration of these drugs, in fact it is not known whether earlier administration will be as safe and perhaps more effective. The concept of prehospital administration of antiplatelet agents in primary PCI was initially investigated with the glycoprotein IIb/IIIa inhibitor abciximab, that was associated with a higher rate of Thrombolysis in Myocardial Infarction flow grade 3 before primary PCI and lower rates of ischemic events, in comparison with placebo.6 Even more studies confirmed the benefit of earlier administration of glycoprotein IIb/IIIa inhibitors in patients with STEMI, especially in those presenting very soon after symptom onset.7-11 However, the benefit was less certain in patients at lower risk for ischemic events or presenting later.12,13 Various studies and meta-analyses suggested that pretreatment with clopidogrel in individuals with STEMI could reduce the rate of ischemic events without excess bleeding,14-16 but its effectiveness may be limited by its slow onset of actions and the variable response.